These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

331 related articles for article (PubMed ID: 33668530)

  • 1. The Treatment of Lung Involvement in Systemic Sclerosis.
    Ruaro B; Confalonieri M; Matucci-Cerinic M; Salton F; Confalonieri P; Santagiuliana M; Citton GM; Baratella E; Bruni C
    Pharmaceuticals (Basel); 2021 Feb; 14(2):. PubMed ID: 33668530
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interstitial lung disease associated with systemic sclerosis (SSc-ILD).
    Cottin V; Brown KK
    Respir Res; 2019 Jan; 20(1):13. PubMed ID: 30658650
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interstitial lung disease in systemic sclerosis.
    Bussone G; Mouthon L
    Autoimmun Rev; 2011 Mar; 10(5):248-55. PubMed ID: 20863911
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Impact of Progressive Pulmonary Fibrosis in Systemic Sclerosis-Associated Interstitial Lung Disease.
    Martín-López M; Carreira PE
    J Clin Med; 2023 Oct; 12(20):. PubMed ID: 37892818
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systemic sclerosis-associated interstitial lung disease.
    Perelas A; Silver RM; Arrossi AV; Highland KB
    Lancet Respir Med; 2020 Mar; 8(3):304-320. PubMed ID: 32113575
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cyclophosphamide for connective tissue disease-associated interstitial lung disease.
    Barnes H; Holland AE; Westall GP; Goh NS; Glaspole IN
    Cochrane Database Syst Rev; 2018 Jan; 1(1):CD010908. PubMed ID: 29297205
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interstitial Lung Disease in Systemic Sclerosis: Focus on Early Detection and Intervention.
    Fischer A; Patel NM; Volkmann ER
    Open Access Rheumatol; 2019; 11():283-307. PubMed ID: 31849543
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Autologous stem-cell transplantation in systemic sclerosis-associated interstitial lung disease: early action in selected patients rather than escalation therapy for all.
    Spierings J; Chiu YH; Voortman M; van Laar JM
    Ther Adv Musculoskelet Dis; 2021; 13():1759720X211035196. PubMed ID: 34394749
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Interstitial lung disease in systemic sclerosis].
    Mouthon L; Berezné A; Brauner M; Kambouchner M; Guillevin L; Valeyre D
    Presse Med; 2006 Dec; 35(12 Pt 2):1943-51. PubMed ID: 17159721
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expert consensus on the management of systemic sclerosis-associated interstitial lung disease.
    Rahaghi FF; Hsu VM; Kaner RJ; Mayes MD; Rosas IO; Saggar R; Steen VD; Strek ME; Bernstein EJ; Bhatt N; Castelino FV; Chung L; Domsic RT; Flaherty KR; Gupta N; Kahaleh B; Martinez FJ; Morrow LE; Moua T; Patel N; Shlobin OA; Southern BD; Volkmann ER; Khanna D
    Respir Res; 2023 Jan; 24(1):6. PubMed ID: 36624431
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Treatment of systemic sclerosis-associated interstitial lung disease].
    Prasse A; Bonella F; Müller-Ladner U; Witte T; Hunzelmann N; Distler J
    Z Rheumatol; 2020 Apr; 79(3):294-303. PubMed ID: 31754786
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current and future perspectives on management of systemic sclerosis-associated interstitial lung disease.
    Distler O; Volkmann ER; Hoffmann-Vold AM; Maher TM
    Expert Rev Clin Immunol; 2019 Oct; 15(10):1009-1017. PubMed ID: 31566449
    [No Abstract]   [Full Text] [Related]  

  • 13. Mycophenolate mofetil as a therapeutic agent for interstitial lung diseases in systemic sclerosis.
    Ueda T; Sakagami T; Kikuchi T; Takada T
    Respir Investig; 2018 Jan; 56(1):14-20. PubMed ID: 29325675
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interstitial lung disease in systemic sclerosis: data from the spanish scleroderma study group.
    Sánchez-Cano D; Ortego-Centeno N; Callejas JL; Fonollosa Plá V; Ríos-Fernández R; Tolosa-Vilella C; Espinosa-Garriga G; Colunga-Argüelles D; Egurbide-Arberas MV; Rubio-Rivas M; Freire M; Ríos-Blanco JJ; Trapiella-Martínez L; Rodríguez-Carballeira M; Marín-Ballvé A; Pla-Salas X; Simeón-Aznar CP
    Rheumatol Int; 2018 Mar; 38(3):363-374. PubMed ID: 29322341
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interstitial lung disease in systemic sclerosis: where do we stand?
    Cappelli S; Bellando Randone S; Camiciottoli G; De Paulis A; Guiducci S; Matucci-Cerinic M
    Eur Respir Rev; 2015 Sep; 24(137):411-9. PubMed ID: 26324802
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Interstitial lung disease in systemic sclerosis].
    Mouthon L; Berezné A; Brauner M; Kambouchner M; Guillevin L; Valeyre D
    Rev Mal Respir; 2007 Oct; 24(8):1035-46. PubMed ID: 18033190
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elevated serum Krebs von den Lungen-6 in systemic sclerosis: a marker of lung fibrosis and severity of the disease.
    Benyamine A; Heim X; Resseguier N; Bertin D; Gomez C; Ebbo M; Harlé JR; Kaplanski G; Rossi P; Bardin N; Granel B
    Rheumatol Int; 2018 May; 38(5):813-819. PubMed ID: 29455320
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of Systemic Sclerosis-Associated Interstitial Lung Disease With and Without Pulmonary Hypertension on Survival: A Large Cohort Study of the German Network for Systemic Sclerosis.
    Moinzadeh P; Bonella F; Oberste M; Weliwitage J; Blank N; Riemekasten G; Müller-Ladner U; Henes J; Siegert E; Günther C; Kötter I; Pfeiffer C; Schmalzing M; Zeidler G; Korsten P; Susok L; Juche A; Worm M; Jandova I; Ehrchen J; Sunderkötter C; Keyßer G; Ramming A; Schmeiser T; Kreuter A; Lorenz HM; Hunzelmann N; Kreuter M
    Chest; 2024 Jan; 165(1):132-145. PubMed ID: 37582424
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Procollagen Type I and III Aminoterminal Propeptide Levels and Severity of Interstitial Lung Disease in Mexican Women With Progressive Systemic Sclerosis.
    Gonzalez-Lopez L; Rocha-Muñoz AD; Olivas-Flores EM; Garcia-Gonzalez A; Peguero-Gómez AR; Flores-Navarro J; Villa-Manzano AI; Zavaleta-Muñiz SA; Salazar-Paramo M; Mejía M; Juárez-Contreras P; Vazquez-Del Mercado M; Cardona-Muñoz EG; Trujillo-Hernández B; Nava-Zavala AH; Gamez-Nava JI
    Arch Bronconeumol; 2015 Sep; 51(9):440-8. PubMed ID: 25301411
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systemic sclerosis associated interstitial lung disease - individualized immunosuppressive therapy and course of lung function: results of the EUSTAR group.
    Adler S; Huscher D; Siegert E; Allanore Y; Czirják L; DelGaldo F; Denton CP; Distler O; Frerix M; Matucci-Cerinic M; Mueller-Ladner U; Tarner IH; Valentini G; Walker UA; Villiger PM; Riemekasten G;
    Arthritis Res Ther; 2018 Jan; 20(1):17. PubMed ID: 29382380
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.